Document is current
Any future updates will be listed below
-
Authors
Liu, David
Lin, Jia-Ren https://orcid.org/0000-0003-4702-7705
Robitschek, Emily J.
Kasumova, Gyulnara G.
Heyde, Alex
Shi, Alvin
Kraya, Adam
Zhang, Gao
Moll, Tabea
Frederick, Dennie T.
Chen, Yu-An https://orcid.org/0000-0001-7228-4696
Wang, Shu
Schapiro, Denis https://orcid.org/0000-0002-9391-5722
Ho, Li-Lun
Bi, Kevin
Sahu, Avinash
Mei, Shaolin
Miao, Benchun
Sharova, Tatyana
Alvarez-Breckenridge, Christopher
Stocking, Jackson H. https://orcid.org/0000-0003-2759-2125
Kim, Tommy
Fadden, Riley
Lawrence, Donald
Hoang, Mai P. https://orcid.org/0000-0002-1406-7981
Cahill, Daniel P.
Malehmir, Mohsen https://orcid.org/0000-0001-6915-5850
Nowak, Martin A. https://orcid.org/0000-0001-5489-0908
Brastianos, Priscilla K. https://orcid.org/0000-0003-4470-8425
Lian, Christine G.
Ruppin, Eytan https://orcid.org/0000-0002-7862-3940
Izar, Benjamin https://orcid.org/0000-0003-2379-6702
Herlyn, Meenhard https://orcid.org/0000-0003-0839-0739
Van Allen, Eliezer M. https://orcid.org/0000-0002-0201-4444
Nathanson, Katherine https://orcid.org/0000-0002-6740-0901
Flaherty, Keith T.
Sullivan, Ryan J. https://orcid.org/0000-0001-5344-6645
Kellis, Manolis https://orcid.org/0000-0001-7113-9630
Sorger, Peter K. https://orcid.org/0000-0002-3364-1838
Boland, Genevieve M. https://orcid.org/0000-0002-7522-6173
-
Funding
Funding for this research was provided by:
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
U.S. Department of Defense (PRCRP WX1XWH-16-1-0119 (CA150619), PRCRP WX1XWH-16-1-0119 (CA150619))
Conquer Cancer Foundation (Young Investigator Award)
Damon Runyon Cancer Research Foundation
Society for Immunotherapy of Cancer
U.S. Department of Health & Human Services | National Institutes of Health (K08CA234458, P01 CA114046; P50 CA174523; U54 CA224070, U54-CA225088)
Doris Duke Charitable Foundation (Clinical Scientist Development Award)
Broad Institute (BroadNext10)
- License Information
-
More Information
Article History
Received: 21 October 2019
Accepted: 24 March 2021
First Online: 3 May 2021
Competing interests
: D.L. reports funding by a postdoctoral fellowship from the Society for Immunotherapy of Cancers which is funded in part by an educational grant from Bristol-Meyers Squibb (BMS). BMS has had no input into the conception, conduct or reporting of the submitted work. D.C. has received consulting (GSK, Lilly, Boston Pharmaceuticals) and travel/speaking (Merck) support outside the scope of the present work. G.M.B. had sponsored research agreements with Takeda Oncology, Palleon Pharmaceuticals and Olink Proteomics, which were not used to support this work. She served as a speaker for Novartis and on scientific advisory boards for Nektar Therapeutics and Novartis and consults for Merck, all of which are outside the scope of this work. P.K.B has consulted for Angiochem, Genentech-Roche, Lilly, Tesaro, Voyager Therapeutics, ElevateBio, Pfizer (Array), Pfizer, SK Life Sciences and Dantari, received grant/research support (to Massachusetts General Hospital) from Merck, BMS and Lilly and honoraria from Merck, Pfizer, Genentech-Roche and Lilly, outside the scope of this present work. R.J.S. has served as consultant and/or on Scientific Advisory Boards for Asana Biosciences, AstraZeneca, BMS, Eisai, Iovance, Merck, Novartis, Oncosec, Pfizer, Replimune and reports research funding from Merck outside the scope of this present work. A.S. has received consulting (Lead Pharma, Checkmate and C-reveal Therapeutics) support outside the scope of the present work. K.T.F. has/had served on the Board of Directors of Loxo Oncology, Clovis Oncology, Strata Oncology, Vivid Biosciences, Checkmate Pharmaceuticals and Kinnate Pharmaceuticals; Corporate Advisory Board of X4 Pharmaceuticals; Scientific Advisory Boards of PIC Therapeutics, Sanofi, Amgen, Asana, Adaptimmune, Aeglea, Shattuck Labs, Tolero, Apricity, Oncoceutics, Fog Pharma, Neon, Tvardi, xCures, Monopteros and Vibliome; and as consultant to Lilly, Novartis, Genentech, BMS, Merck, Takeda, Verastem, Boston Biomedical, Pierre Fabre and Debiopharm; and received research funding from Novartis and Sanofi. B.I. is a consultant for Merck and Volastra Therapeutics. A.S. has received consulting (Lead Pharma, Checkmate and C-reveal Therapeutics) support outside the scope of the present work. P.K.S. is a member of the Board of Directors of Applied Biomath and Glencoe Software and member of the SAB for RareCyte and NanoString; he has equity in the first three of these companies. In the last 5 years the Sorger laboratory has received research funding from Novartis and Merck. E.M.V.A. has consulted or advised for Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Janssen, Manifold Bio and Monte Rosa and holds equity in Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Manifold Bio, Microsoft and Monte Rosa; has received research support from Novartis and BMS, travel reimbursement from Roche/Genentech and has Institutional patents filed on chromatin mutations and immunotherapy response and methods for clinical interpretation. All other authors declare no competing interests.
